Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
4(80.0%)
Phase 1
1(20.0%)
5Total
N/A(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01504958Not ApplicableCompleted

Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients

Role: collaborator

NCT02166827Not ApplicableTerminated

Effects of a NeuroAD System, for the Treatment of Alzheimer Disease

Role: lead

NCT01825330Not ApplicableCompleted

Effect of NeuroAD on the Cognitive Function of Alzheimer Patients

Role: lead

NCT01825317Not ApplicableCompleted

Effect of NeuroAD on Alzheimer Patients

Role: lead

NCT01168245Phase 1Completed

TMS Stimulation and Cognitive Training in Alzheimer Patients

Role: lead

All 5 trials loaded